J Korean Neuropsychiatr Assoc.  2019 Feb;58(1):12-17. 10.4306/jknpa.2019.58.1.12.

New Insights into the Molecular and Cellular Mechanism of Antipsychotics

• Kim SH

• KMID: 2439023
• DOI: http://doi.org/10.4306/jknpa.2019.58.1.12

Abstract

The serendipitous discovery of drugs with antipsychotic action has provided a clue to understanding the pathogenesis of psychotic disorders and to develop so called "˜antipsychotics' drugs. From the "˜dopamine hypothesis' to current molecular psychiatry findings, researchers have endeavored to improve the understanding of the mechanism of action of antipsychotic drugs. Signaling molecules were examined as novel intracellular targets of antipsychotic action. The findings regarding the effects of antipsychotics on inflammation, metabolism, and cellular fate have helped conceptualize the biological action of antipsychotics. This review summarizes the current knowledge of the molecular psychiatry findings regarding the action mechanisms of antipsychotics. The accumulation of research findings will lead to a better understanding of the pathogenesis of schizophrenia and its treatment mechanism.

Keyword

Antipsychotics; Psychopharmacology; Signal transduction

MeSH Terms

Antipsychotic Agents*
Inflammation
Metabolism
Psychopharmacology
Psychotic Disorders
Schizophrenia
Signal Transduction
Antipsychotic Agents

Reference

1. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh). 1963; 20:140–144.

2. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991; 148:1474–1486.

3. Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, et al. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science. 1984; 225:954–957.

4. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. J Neuropsychiatry Clin Neurosci. 1996; 8:223–226.

5. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003; 60:553–564.

6. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382:951–962.

7. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007; 18:39–60.

8. Hippius H. A historical perspective of clozapine. J Clin Psychiatry. 1999; 60:Suppl 12. 22–23.

9. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017; 14:750–761.

10. Amato D. Serotonin in antipsychotic drugs action. Behav Brain Res. 2015; 277:125–135.

11. Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol. 2012; 87–124.

12. Forray C, Buller R. Challenges and opportunities for the development of new antipsychotic drugs. Biochem Pharmacol. 2017; 143:10–24.

13. Kondej M, Stepnicki P, Kaczor AA. Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci. 2018; 19:E3105.

14. Molteni R, Calabrese F, Racagni G, Fumagalli F, Riva MA. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther. 2009; 124:74–85.

15. Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, et al. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci. 2008; 11:932–939.

16. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 1998; 281:838–842.

17. Wang H, Farhan M, Xu J, Lazarovici P, Zheng W. The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget. 2017; 8:53791–53803.

18. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A. 2008; 105:13656–13661.

19. Urs NM, Gee SM, Pack TF, McCorvy JD, Evron T, Snyder JC, et al. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci U S A. 2016; 113:E8178–E8186.

20. Halene TB, Siegel SJ. Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle. J Pharmacol Exp Ther. 2008; 326:230–239.

21. Lipina TV, Palomo V, Gil C, Martinez A, Roder JC. Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology. 2013; 64:205–214.

22. Pandey MK, DeGrado TR. Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics. 2016; 6:571–593.

23. Wiescholleck V, Manahan-Vaughan D. PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis. Transl Psychiatry. 2012; 2:e89.

24. Hanson ND, Owens MJ, Nemeroff CB. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology. 2011; 36:2589–2602.

25. Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci. 2015; 69:243–258.

26. Nandra KS, Agius M. The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatr Danub. 2012; 24:Suppl 1. S95–S99.

27. Gassó P, Mas S, Molina O, Bernardo M, Lafuente A, Parellada E. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 36:71–77.

28. Dakir EH, Pickard A, Srivastava K, McCrudden CM, Gross SR, Lloyd S, et al. The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer. Oncotarget. 2018; 9:34889–34910.

29. Roney MSI, Park SK. Antipsychotic dopamine receptor antagonists, cancer, and cancer stem cells. Arch Pharm Res. 2018; 41:384–408.

30. Wu CH, Bai LY, Tsai MH, Chu PC, Chiu CF, Chen MY, et al. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-a drug repurposing strategy. Sci Rep. 2016; 6:27540.

31. Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, et al. Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep. 2018; 8:15753.

32. Sachlos E, Risueño RM, Laronde S, Shapovalova Z, Lee JH, Russell J, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012; 149:1284–1297.

33. Frade JM, Ovejero-Benito MC. Neuronal cell cycle: the neuron itself and its circumstances. Cell Cycle. 2015; 14:712–720.

34. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013; 19:983–997.

35. Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, et al. Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry. 2015; 20:126–132.

36. Merenlender-Wagner A, Shemer Z, Touloumi O, Lagoudaki R, Giladi E, Andrieux A, et al. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy. 2014; 10:2324–2332.

37. Schneider JL, Miller AM, Woesner ME. Autophagy and schizophrenia: a closer look at how dysregulation of neuronal cell homeostasis influences the pathogenesis of schizophrenia. Einstein J Biol Med. 2016; 31:34–39.

38. Ranjan A, Srivastava SK. Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis. Sci Rep. 2016; 6:26165.

39. Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013; 34:2080–2089.

40. Yin YC, Lin CC, Chen TT, Chen JY, Tsai HJ, Wang CY, et al. Clozapine induces autophagic cell death in non-small cell lung cancer cells. Cell Physiol Biochem. 2015; 35:945–956.

41. Kim SH, Park S, Yu HS, Ko KH, Park HG, Kim YS. The antipsychotic agent clozapine induces autophagy via the AMPK-ULK1-Beclin1 signaling pathway in the rat frontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 81:96–104.

42. Choi Y, Jeong HJ, Liu QF, Oh ST, Koo BS, Kim Y, et al. Clozapine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer’s disease. Mol Neurobiol. 2017; 54:450–460.

43. Tourjman V, Kouassi É, Koué MÈ, Rocchetti M, Fortin-Fournier S, Fusar-Poli P, et al. Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res. 2013; 151:43–47.

44. Müller N, Myint AM, Krause D, Weidinger E, Schwarz MJ. Anti-inflammatory treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 42:146–153.

45. Jeon S, Kim SH, Shin SY, Lee YH. Clozapine reduces Toll-like receptor 4/NF-κB-mediated inflammatory responses through inhibition of calcium/calmodulin-dependent Akt activation in microglia. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 81:477–487.

46. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004; 25:4–7.

47. Fonseka TM, Müller DJ, Kennedy SH. Inflammatory cytokines and antipsychotic-induced weight gain: review and clinical implications. Mol Neuropsychiatry. 2016; 2:1–14.

48. Cui D, Peng Y, Zhang C, Li Z, Su Y, Qi Y, et al. Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy. J Clin Invest. 2018; 128:4997–5007.

49. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007; 104:3456–3459.

50. Kim MK, Kim SH, Yu HS, Park HG, Kang UG, Ahn YM, et al. The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex. Int J Neuropsychopharmacol. 2012; 15:907–917.

51. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry. 2008; 13:918–929.

52. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci. 2009; 30:55–60.

53. Hyman SE. Target practice: HDAC inhibitors for schizophrenia. Nat Neurosci. 2012; 15:1180–1181.

54. Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 2012; 15:1245–1254.

55. De la Fuente Revenga M, Ibi D, Saunders JM, Cuddy T, Ijaz MK, Toneatti R, et al. HDAC2-dependent antipsychotic-like effects of chronic treatment with the HDAC Inhibitor SAHA in mice. Neuroscience. 2018; 388:102–117.

56. Ibi D, De la Fuente Revenga M, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, et al. Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nat Neurosci. 2017; 20:1247–1259.

57. Swathy B, Banerjee M. Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy. Epigenomics. 2017; 9:721–736.

58. Dong E, Grayson DR, Guidotti A, Costa E. Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics. 2009; 1:201–211.

59. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A. 2008; 105:13614–13619.

60. Guidotti A, Grayson DR. DNA methylation and demethylation as targets for antipsychotic therapy. Dialogues Clin Neurosci. 2014; 16:419–429.

61. Kim SH, Lee HY, Yi H, Ahn YM, Kim YS. Haloperidol induces demethylation and expression of the dual specificity phosphatase 6 gene in MIA PaCa-2 human pancreatic cancer cells. Life Sci. 2012; 91:1317–1322.

62. Luoni A, Riva MA. MicroRNAs and psychiatric disorders: from aetiology to treatment. Pharmacol Ther. 2016; 167:13–27.

63. Swathy B, Saradalekshmi KR, Nair IV, Nair C, Banerjee M. Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs. Epigenomics. 2017; 9:811–821.